Frank Tufaro
Amministratore Delegato presso DNAtrix, Inc.
Patrimonio netto: 33 064 $ in data 30/04/2024
Profilo
Frank Tufaro is the founder of Medigene, Inc., Nurel Therapeutics, Inc., NeuroVir Therapeutic, Inc. He is currently the Chief Executive Officer & Director at DNAtrix, Inc. and a Director at Protocol Intelligence, Inc. Previously, he served as the Chief Executive Officer of Allera Health Products, Inc. and President, Chief Executive Officer & Director of DNAtrix, Inc. He was also a Professor of Microbiology & Immunology at the University of British Columbia.
Additionally, he held the position of Chief Operating Officer at Theriva Biologics SL.
In 2020, he became the President of Opa Therapeutics, Inc. and in 2022, he served as the Chief Operating Officer at Theriva Biologics, Inc. Dr. Tufaro obtained his undergraduate and doctorate degrees from McGill University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
THERIVA BIOLOGICS, INC.
0.47% | 25/03/2024 | 80 645 ( 0.47% ) | 33 064 $ | 30/04/2024 |
Posizioni attive di Frank Tufaro
| Società | Posizione | Inizio |
|---|---|---|
Protocol Intelligence, Inc.
 Protocol Intelligence, Inc. Packaged SoftwareTechnology Services Protocol Intelligence, Inc. is an American company that is developing an intelligent navigational system for myeloma oncologists. The system includes software, human data curation, and decision support that advises physicians on which drugs to use and when to use them, optimized for each patient's evolving needs and physician-imposed constraints. | Direttore/Membro del Consiglio | - |
DNAtrix, Inc.
 DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Amministratore Delegato | - |
Precedenti posizioni note di Frank Tufaro
| Società | Posizione | Fine |
|---|---|---|
| THERIVA BIOLOGICS, INC. | Direttore operativo | 10/05/2023 |
| Opa Therapeutics, Inc. | Presidente | 01/03/2022 |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Amministratore Delegato | 01/12/2019 |
| University of British Columbia | Corporate Officer/Principal | 01/01/2002 |
VCN Biosciences SL
 VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Direttore operativo | - |
Formazione di Frank Tufaro
| McGill University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| THERIVA BIOLOGICS, INC. | Health Technology |
| Aziende private | 8 |
|---|---|
Allera Health Products, Inc.
 Allera Health Products, Inc. Specialty StoresRetail Trade Allera Health Products, Inc. provides healthcare products. It develops supplements that enhance immune system and drugs that fight illness and diseases. Its products include ProLigna and ImmunExtra. The company was founded in 2005 and is headquartered in St. Petersburg, FL. | Retail Trade |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Electronic Technology |
MediGene, Inc.
 MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
NeuroVir Therapeutic, Inc.
 NeuroVir Therapeutic, Inc. Pharmaceuticals: MajorHealth Technology Part of MediGene AG, NeuroVir Therapeutic, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company is based in San Diego, CA. The company was founded by Michael R. Hayden, Frank Tufaro. NeuroVir Therapeutic was acquired by MediGene AG on January 12, 2001 for $53 million. | Health Technology |
Nurel Therapeutics, Inc.
 Nurel Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nurel Therapeutics, Inc. was a biotechnology company. The company develops products to treat and manage pain and peripheral nerve damage and also develops products to vascular diseases. The company's products use a proprietary drug delivery technology derived from an 'inert' herpes simplex virus that provides gene based medicine. The company was headquartered in Pittsburgh, PA. | Health Technology |
VCN Biosciences SL
VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Commercial Services |
| Opa Therapeutics, Inc. | |
Protocol Intelligence, Inc.
Protocol Intelligence, Inc. Packaged SoftwareTechnology Services Protocol Intelligence, Inc. is an American company that is developing an intelligent navigational system for myeloma oncologists. The system includes software, human data curation, and decision support that advises physicians on which drugs to use and when to use them, optimized for each patient's evolving needs and physician-imposed constraints. | Technology Services |
- Borsa valori
- Insiders
- Frank Tufaro
